• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项关于(治疗性泻下)对肠道菌群影响的临床研究,特别涉及肥胖问题。

A clinical study on (therapeutic purgation) over the gut flora with special reference to obesity.

作者信息

Chaturvedi Ashutosh, Nath Gopal, Yadav Virender Bhadur, Antiwal Meera, Shakya Niharika, Swathi C, Singh Jai Prakash

机构信息

Department of Kayachikitsa and Panchakarma and, Azamgarh, Uttar Pradesh, India.

Department of Microbiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Azamgarh, Uttar Pradesh, India.

出版信息

Ayu. 2019 Jul-Sep;40(3):179-184. doi: 10.4103/ayu.AYU_302_19. Epub 2020 Aug 8.

DOI:10.4103/ayu.AYU_302_19
PMID:33281395
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7685265/
Abstract

BACKGROUND

Altered gut flora is associated with the pathogenesis of both intestinal and extra‑intestinal disorders. Aetiology of obesity is associated with mechanisms such as short chain fatty acid production, stimulation of hormones, chronic low‑grade inflammation, lipoprotein and bile acid metabolism and increased endocannabinoid. Receptor system tone have been suggested to explain the role of gut microbiota of obesity. The (Ayurvedic purification methods) claims the management of metabolic disorders hence this work provides the target specific evidence for the clinical studies. The proposed project is aimed to explore the particular molecular mechanism and, to make this therapy more evidence based. Hence, it was hypothesized that ‑based intervention such as (therapeutic purgation) may influence microbiota and help in the management of the obesity.

MATERIALS AND METHODS

The study was conducted to explore the effect of over the gut flora; therefore, total of 19 patients with diagnosed with obesity were included and received the intervention. Before and after , a stool sample was collected and processed for the enterobacterial repetitive intergenic consensus ‑polymerase chain reaction to find the changes over the facultative aerobic bacteria.

RESULTS

It was found that is effective in the management of the obesity as it helps to reduce colonization of aerobic bacteria. After and after follow‑up also, it showed the correction of the gut flora dysbiosis, thus initiated the weight loss mechanism in the body, resulting in diminution in the signs and symptoms of obesity.

CONCLUSION

is effective in the management of the obesity due to reduction in the colonization and is effective over the gut flora dysbiosis.

摘要

背景

肠道菌群改变与肠道及肠道外疾病的发病机制相关。肥胖的病因与短链脂肪酸生成、激素刺激、慢性低度炎症、脂蛋白和胆汁酸代谢以及内源性大麻素增加等机制有关。有人提出受体系统调节来解释肠道微生物群在肥胖中的作用。(阿育吠陀净化方法)宣称可管理代谢紊乱,因此本研究为临床研究提供了靶点特异性证据。拟开展的项目旨在探索特定分子机制,并使该疗法更具循证依据。因此,我们假设基于(治疗性泻下)的干预可能影响微生物群,并有助于肥胖的管理。

材料与方法

本研究旨在探讨(治疗性泻下)对肠道菌群的影响;因此,共纳入19例诊断为肥胖的(治疗性泻下)患者并接受干预。在(治疗性泻下)前后,收集粪便样本并进行肠杆菌重复基因间共识-聚合酶链反应,以发现兼性需氧菌的变化。

结果

发现(治疗性泻下)对肥胖管理有效,因为它有助于减少需氧菌的定植。在(治疗性泻下)后及随访后,也显示肠道菌群失调得到纠正,从而启动了体内的体重减轻机制,导致肥胖的体征和症状减轻。

结论

(治疗性泻下)因减少(需氧菌)定植而对肥胖管理有效,且对肠道菌群失调有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/541e/7685265/7a870c8c3ff4/AYU-40-179-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/541e/7685265/7a870c8c3ff4/AYU-40-179-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/541e/7685265/7a870c8c3ff4/AYU-40-179-g001.jpg

相似文献

1
A clinical study on (therapeutic purgation) over the gut flora with special reference to obesity.一项关于(治疗性泻下)对肠道菌群影响的临床研究,特别涉及肥胖问题。
Ayu. 2019 Jul-Sep;40(3):179-184. doi: 10.4103/ayu.AYU_302_19. Epub 2020 Aug 8.
2
Effect and Mechanism of Virechana Karma (Therapeutic Purgation) Over Fructose-Induced Metabolic Syndrome: An Experimental Study.维勒查那疗法(治疗性泻下)对果糖诱导的代谢综合征的作用及机制:一项实验研究
J Evid Based Complementary Altern Med. 2016 Jul;21(3):194-201. doi: 10.1177/2156587215596283. Epub 2015 Jul 22.
3
Analysis of Virechana karma with Danti avaleha: A retrospective study.用旃檀膏分析净肠疗法:一项回顾性研究。
J Ayurveda Integr Med. 2015 Oct-Dec;6(4):300-4. doi: 10.4103/0975-9476.172420.
4
Efficacy of (therapeutic purgation) followed by (cow ghee) in the management of (oligozoospermia): A clinical study.(治疗性泻下)继以(牛酥油)治疗少精子症的疗效:一项临床研究。
Ayu. 2019 Jan-Mar;40(1):27-33. doi: 10.4103/ayu.AYU_275_18.
5
A standard controlled clinical study on and in the management of dyslipidemia ().一项关于[具体药物名称1]和[具体药物名称2]治疗血脂异常([具体病症名称])的标准对照临床研究。
Ayu. 2016 Jan-Mar;37(1):32-37. doi: 10.4103/ayu.AYU_14_15.
6
Role of Virechana Karma in cure and prevention of recurrence of Vicharchika (Eczema).泻下疗法在治疗和预防湿疮(湿疹)复发中的作用。
Ayu. 2012 Oct;33(4):505-10. doi: 10.4103/0974-8520.110526.
7
Role of Gut Microbiota in the Aetiology of Obesity: Proposed Mechanisms and Review of the Literature.肠道微生物群在肥胖病因学中的作用:提出的机制及文献综述
J Obes. 2016;2016:7353642. doi: 10.1155/2016/7353642. Epub 2016 Sep 15.
8
Role of and in the management of (oligozoospermia): A pilot study.[具体物质]和[具体物质]在[少精子症]管理中的作用:一项初步研究。 (注:原文中部分内容缺失,这里用[具体物质]等表示缺失部分)
Ayu. 2016 Apr-Jun;37(2):113-119. doi: 10.4103/ayu.AYU_71_15.
9
Ayurvedic Therapies to Target the Microbiome: Evidence and Possibilities.阿育吠陀疗法靶向微生物组:证据与可能性。
Altern Ther Health Med. 2024 Feb;30(2):76-83.
10
A comparative clinical study of Nyagrodhadi Ghanavati and Virechana Karma in the management of Madhumeha.Nyagrodhadi Ghanavati与催吐疗法治疗糖尿病的比较临床研究
Ayu. 2010 Jul;31(3):300-4. doi: 10.4103/0974-8520.77152.

本文引用的文献

1
Identification of Altered Metabolomic Profiles Following a Panchakarma-based Ayurvedic Intervention in Healthy Subjects: The Self-Directed Biological Transformation Initiative (SBTI).基于健康受试者的帕那卡玛疗法的 Ayurvedic 干预后代谢组学谱的改变鉴定:自我导向的生物转化计划(SBTI)。
Sci Rep. 2016 Sep 9;6:32609. doi: 10.1038/srep32609.
2
Prevalence of metabolic syndrome in urban India.印度城市地区代谢综合征的患病率。
Cholesterol. 2011;2011:920983. doi: 10.1155/2011/920983. Epub 2011 May 19.
3
Benchmarking best practices in weight loss surgery.
减肥手术最佳实践的基准测试。
Curr Probl Surg. 2010 Feb;47(2):79-174. doi: 10.1067/j.cpsurg.2009.11.003.
4
Obesity: genetic, molecular, and environmental aspects.肥胖症:遗传、分子及环境因素
Am J Med Genet A. 2007 Dec 15;143A(24):3016-34. doi: 10.1002/ajmg.a.32035.
5
Pharmacotherapy of obesity: currently marketed and upcoming agents.肥胖症的药物治疗:目前已上市及即将上市的药物
Am J Cardiovasc Drugs. 2002;2(4):245-53. doi: 10.2165/00129784-200202040-00004.